FrancophonIA/ELRC3.0 huggingface dataset:
English: Since tenofovir disoproxil can cause renal toxicity, close monitoring of renal function is recommended in any patient with mild renal impairment treated with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (see sections 4.2, 4.4 and 5.2).
Croatian: Tenofovirdizoproksil može prouzročiti bubrežnu toksičnost pa se preporučuje pomno nadziranje funkcije bubrega u svakog bolesnika s blagim oštećenjem funkcije bubrega koji se liječi lijekom Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (vidjeti dijelove 4.2, 4.4 i 5.2).
English: Once you start taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, look out for:
Croatian: Nakon što započnete s uzimanjem Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, pazite na sljedeće:
English: Clarithromycin 14-hydroxymetabolite: AUC: ↑ 34% (↑ 18 to ↑ 53)
Croatian: klaritromicin 14-hidroksimetabolit: AUC: ↑ 34% (↑ 18 do ↑ 53) Cmax: ↑ 49% (↑ 32 do ↑ 69)
English: Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Krka prior to initiation of their first antiretroviral treatment regimen (see sections 4.4 and 5.1).
Croatian: Prije započinjanja prvog režima antiretrovirusnog liječenja, bolesnici nisu smjeli doživjeti virološki neuspjeh na bilo koju raniju antiretrovirusnu terapiju i mora biti ustanovljeno da nisu nosili sojeve virusa s mutacijama koje pokazuju značajnu rezistenciju na bilo koju od tri komponente koje sadrži Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (vidjeti dijelove 4.4 i 5.1).
English: AUC: ↑ 21% (↑ 10 to ↑ 34) Cmax: ↑ 14% (↑ 4 to ↑ 26) Cmin: ↑ 25% (↑ 7 to ↑ 46) (inhibition of CYP-mediated oxidative metabolism)
Croatian: AUC: ↑ 21% (↑ 10 do ↑ 34) Cmax: ↑ 14% (↑ 4 do ↑ 26) Cmin: ↑ 25% (↑ 7 do ↑ 46) (inhibicija oksidativnog metabolizma u kojem sudjeluju enzimi CYP)
English: Co-administration of efavirenz/emtricitabine/tenofovir disoproxil with elbasvir/grazoprevir is contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir.
Croatian: Istodobna primjena efavirenza/emtricitabina/tenofovi rdizoproksila i elbasvira/grazoprevira kontraindicirana je jer može dovesti do gubitka virološkog odgovora na elbasvir/grazoprevir.
English: As Efavirenz/Emtricitabine/Tenofovir disoproxil Krka contains efavirenz, emtricitabine and tenofovir disoproxil, any interactions that have been identified with these agents individually may occur with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Obzirom da Efavirenz/Emtricitabine/Tenofovir disoproxil Krka sadrži efavirenz, emtricitabin i tenofovirdizoproksil, sve interakcije koje su utvrđene u zasebnoj primjeni tih lijekova mogu se pojaviti i s lijekom Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be taken with any of these medicines.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka se ne smije uzimati zajedno s bilo kojim od tih lijekova.
English: Where discontinuation of therapy with one of the components of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is indicated or where dose modification is necessary, separate preparations of efavirenz, emtricitabine and tenofovir disoproxil are available.
Croatian: Kada je indiciran prekid terapije jednom od komponenti lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ili kada je nužno prilagođavanje doze, postoje odvojeni pripravci efavirenza, emtricitabina i tenofovirdizoproksila.
English: Discontinuation of efavirenz/emtricitabine/tenofovir disoproxil therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis.
Croatian: Prekid liječenja efavirenzom/emtricitabinom/tenofovirdizoproksilom u bolesnika istodobno inficiranih HIV-om i HBV-om može biti povezan s teškim akutnim egzacerbacijama hepatitisa.
English: Dose adjustments of calcium channel blockers when coadministered with Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should be guided by clinical response (refer to the Summary of Product Characteristics for the calcium channel blocker).
Croatian: Podešavanja doze blokatora kalcijevih kanala kada se primjenjuju istodobno s lijekom Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka treba usklađivati s kliničkim odgovorom (pogledajte sažetak opisa svojstava lijeka za blokator kalcijevih kanala).
English: Renal function should be closely monitored (see section
Croatian: Nužno je pomno nadzirati funkciju bubrega (vidjeti dio 4.4).
English: How to store Efavirenz/Emtricitabine/Tenofovir disoproxil Krka Contents of the pack and other information
Croatian: Kako čuvati Efavirenz/Emtricitabine/Tenofovir disoproxil Krka Sadržaj pakiranja i druge informacije
English: If a patient misses a dose of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka within 12 hours of the time it is usually taken, the patient should take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka as soon as possible and resume the normal dosing schedule.
Croatian: Ako bolesnik propusti uzeti dozu lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, a prošlo je manje od 12 sati od uobičajenog vremena uzimanja, bolesnik treba što prije uzeti Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i potom ga nastaviti uzimati prema svom normalnom rasporedu.
English: Integrase strand transfer inhibitor Raltegravir/Efavirenz (400 mg single dose/-)
Croatian: Inhibitor prijenosa niza integraze raltegravir/efavirenz (400 mg u jednoj dozi /-)
English: Efavirenz/emtricitabine/tenofovir disoproxil must not be used in patients with severe hepatic impairment (see section 4.3) and is not recommended for patients with moderate hepatic impairment.
Croatian: Efavirenz/emtricitabin/tenofovirdizoproksil se ne smije davati bolesnicima s teškim oštećenjem funkcije jetre (vidjeti dio 4.3) i ne preporučuje se bolesnicima s umjerenim oštećenjem funkcije jetre.
English: Combination of emtricitabine and tenofovir disoproxil
Croatian: Kombinacija emtricitabina i tenofovirdizoproksila
English: Monitoring of renal function is recommended for patients receiving Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (see section 4.4).
Croatian: Preporučuje se praćenje funkcije bubrega u bolesnika koji primaju Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (vidjeti dio 4.4).
English: AUC: ↓ 13% Cmin: ↓ 31% Cmax: ↓ 15% (CYP3A4 induction)
Croatian: AUC: ↓ 13% Cmin: ↓ 31% Cmax: ↓ 15% (indukcija CYP3A4)
English: Microcrystalline cellulose Hydroxypropylcellulose Sodium laurilsulfate Croscarmellose sodium Ferric oxide red (E172) Magnesium stearat Sodium stearyl fumarate
Croatian: Jezgra tablete celuloza, mikrokristalična hidroksipropilceluloza natrijev laurilsulfat karmelozanatrij, umrežena željezov oksid, crveni (E172) magnezijev stearat natrijev stearilfumarat
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended for patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson syndrome) while taking an NNRTI.
Croatian: Uzimanje lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ne preporučuje se bolesnicima u kojih se tijekom uzimanja NNRTI lijekova pojavila po život opasna kožna reakcija (npr. Stevens-Johnsonov sindrom).
English: Cmax: ↑ 11% (↑ 3 to ↑ 19) (CYP3A4 induction)
Croatian: Cmax: ↑ 11% (↑ 3 do ↑ 19) (indukcija CYP3A4)
English: Administration to patients with: a family history of sudden death or of congenital prolongation of the QTc interval on electrocardiograms, or with any other clinical condition known to prolong the QTc interval.
Croatian: Primjena u bolesnika koji imaju: - u obiteljskoj anamnezi iznenadnu smrt ili kongenitalno produljenje QTc intervala na elektrokardiogramu ili neko drugo kliničko stanje za koje je poznato da produljuje QTc interval. - anamnezu simptomatskih srčanih aritmija ili klinički značajne bradikardije ili kongestivnog srčanog zatajenja popraćenog smanjenom ejekcijskom frakcijom lijeve klijetke.
English: Interaction with didanosine Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Croatian: Ne preporučuje se istodobna primjena lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i didanozina jer rezultira 40-60%-tnim povećanjem sistemske izloženosti didanozinu što može povećati rizik od nuspojava povezanih s didanozinom (vidjeti dio 4.5).
English: If you take more Efavirenz/Emtricitabine/Tenofovir disoproxil Krka than you should
Croatian: Ako uzmete više lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka nego što ste trebali
English: This adverse reaction was identified through post-marketing surveillance for either efavirenz, emtricitabine or tenofovir disoproxil.
Croatian: Ova je nuspojava uočena tijekom praćenja koje je nakon stavljanja u promet provedeno za efavirenz, emtricitabin ili tenofovirdizoproksil.
English: Due to similarities with emtricitabine, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with other cytidine analogues, such as lamivudine (see section 4.5).
Croatian: Zbog sličnosti s emtricitabinom, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka se ne smije primjenjivati zajedno s drugim analozima citidina, kao što je lamivudin (vidjeti dio 4.5).
English: The recommended dose of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is one tablet taken orally once daily.
Croatian: Preporučena doza lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka je jedna tableta dnevno primijenjena peroralno.
English: 3, affect lability confusional state aggression
Croatian: 3, konfuzija agresivnost
English: Emtricitabine: AUC: ↔ Cmax: ↔ C24h: ↔
Croatian: emtricitabin: AUC: ↔ Cmax: ↔ C24h: ↔
English: Prior efavirenz/emtricitabine/tenofovir disoproxil components (N=299)
Croatian: Prethodno liječenje komponenatama efavirenza/emtricitabina/tenofovirdizoproksila (N=299)
English: No dose recommendation can be made for the use of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka with carbamazepine.
Croatian: Ne može se dati preporuka doze za primjenu lijeka Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka s karbamazepinom.
English: Discontinuation of efavirenz/emtricitabine/tenofovir disoproxil therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis (see section 4.4).
Croatian: Prekid terapije efavirenzom/emtricitabinom/tenofovirdizoproksilom u bolesnika istodobno inficiranih HIV-om i HBV-om može biti povezan s teškim akutnim egzacerbacijama hepatitisa (vidjeti dio 4.4).
English: No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents.
Croatian: Nema dostupnih podataka koji bi poduprli primjenu kombinacije efavirenza/emtricitabina/tenofovirdizoproksila i drugih antiretrovirusnih tvari.
English: When the two strata were analysed separately, response rates in the stratum with prior PI-treatment were numerically lower for patients switched to efavirenz/emtricitabine/tenofovir disoproxil [92.4% versus 94.0% for the PVR (sensitivity analysis) for efavirenz/emtricitabine/tenofovir disoproxil and SBR patients respectively; a difference (95%CI) of -1.6% (-10.0%, 6.7%).
Croatian: Zasebna analiza dviju skupina pokazala je da su u skupini koja je prethodno liječena inhibitorima proteaze stope odgovora numerički manje u bolesnika koji su prešli na efavirenz/emtricitabin/tenofovirdizoproksil [PVR (analiza osjetljivosti) od 92,4% u bolesnika koji su primali efavirenz/emtricitabin/tenofovirdizoproksil u usporedbi s 94,0% u SBR bolesnika: razlika (95%CI) od -1,6% (-10,0%, 6,7%).
English: 13/19 (68%) patients in the efavirenz + emtricitabine + tenofovir disoproxil group and in virus from 21/29 (72%) patients in the efavirenz + lamivudine/zidovudine group.
Croatian: - Genotipska rezistencija na efavirenz, pretežno mutacija K103N, razvila se kod virusa u 13/19 (68%) bolesnika iz skupine efavirenz + emtricitabin + tenofovirdizoproksil te kod virusa u 21/29 (72%) bolesnika u skupini efavirenz + lamivudin/zidovudin.
English: If creatinine clearance is confirmed as < 50 ml/min or serum phosphate decreases to < 1.0 mg/dl then Efavirenz/Emtricitabine /Tenofovir disoproxil Krka therapy should be interrupted.
Croatian: Ako se potvrdi da je vrijednost klirensa kreatinina < 50 ml/min ili je koncentracija fosfata u serumu smanjena na < 1,0 mg/dl, terapija lijekom Efavirenz/Emtricitabine /Tenofovir disoproxil
English: Talk to your doctor or pharmacist before taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: Table 3: Development of resistance in study GS-01-934 through week 144
Croatian: Tablica 3: Razvoj rezistencije u ispitivanju GS-01-934 do 144. tjedna efavirenz+ emtricitabin+ tenofovirdizoproksil (N=244)
English: AUC: ↑ 11% (↑ 5 to ↑ 18) Cmax: ↑ 16% (↑ 6 to ↑ 26) Cmin: ↑ 13% (↑ 1 to ↑ 26) (CYP3A4 induction)
Croatian: AUC: ↑ 11% (↑ 5 do ↑ 18) Cmax: ↑ 16% (↑ 6 do ↑ 26) Cmin: ↑ 13% (↑ 1 do ↑ 26) (indukcija CYP3A4)
English: Exacerbations of hepatitis after discontinuation of treatment In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis may occur after discontinuation of treatment (see section 4.4).
Croatian: U bolesnika s HIV-om koji su istodobno imali infekciju HBV-om, nakon prekida liječenja mogući su klinički i laboratorijski znakovi hepatitisa (vidjeti dio 4.4).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is contraindicated in patients with severe hepatic impairment (see section 4.3) and not recommended in patients with moderate hepatic impairment.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka je kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre (vidjeti dio 4.3) i ne preporučuje se bolesnicima s umjerenim oštećenjem funkcije jetre.
English: Therefore Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be used during breast-feeding.
Croatian: Stoga se Efavirenz/Emtricitabine/Tenofovir disoproxil Krka ne smije primjenjivati tijekom dojenja.
English: The use of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka in children and adolescents has not been studied.
Croatian: Primjena lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka u djece i adolescenata nije ispitana.
English: If you throw up the tablet (within 1 hour after taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka), you should take another tablet.
Croatian: Ako ste povratili tabletu (unutar 1 sata nakon što ste uzeli Efavirenz/Emtricitabine/Tenofovir disoproxil Krka), uzmite drugu tabletu.
English: Due to similarities with emtricitabine, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with other cytidine analogues, such as lamivudine.
Croatian: Zbog sličnosti s emtricitabinom, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka se ne smije primjenjivati istodobno s drugim analozima citidina, kao što je lamivudin.
English: and the mean semen to plasma concentration ratio was approximately 4.0.
Croatian: Srednja vrijednost omjera koncentracija u plazmi naspram krvi bila je približno 1,0 a srednja vrijednost omjera koncentracija u spermi naspram plazme bila je približno 4,0.
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka must be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement or fever.
Croatian: Primjena lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka mora se prekinuti ako se u bolesnika razvije težak osip povezan s nastajanjem mjehura, deskvamacija, uključenost sluznica ili povišena tjelesna temperatura.
English: Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir is not recommended since plasma concentrations of velpatasvir and voxilaprevir are expected to decrease following co-administration with efavirenz leading to reduced therapeutic effect of sofosbuvir/velpatasvir or sofosbuvir/velpatasvir/voxilaprevir (see section
Croatian: Istodobna primjena lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/voksilapreva se ne preporučuje jer se očekuje da će se koncentracija velpatasvira i voksilaprevira u plazmi smanjiti nakon istodobne primjene s efavirenzom što će dovesti do smanjenog terapijskog učinka sofosbuvira/velpatasvira ili sofosbuvira/velpatasvira/voksilaprevira (vidjeti dio 4.5).
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may cause dizziness, impaired concentration and drowsiness.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka može uzrokovati omaglicu, manjak koncentracije i omamljenost.
English: If the patient vomits more than 1 hour after taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka he/she does not need to take another dose.
Croatian: Ako bolesnik povraća nakon više od 1 sata od uzimanja lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, nije potrebno uzeti još jednu dozu.
English: No effect (↔) equals a decrease in mean ratio estimate of ≤ 20% or increase in mean ratio estimate of ≤ 25%
Croatian: Bez učinka (↔) odgovara smanjenju procijenjenog omjera srednjih vrijednosti za ≤ 20% ili povećanju procijenjenog omjera srednjih vrijednosti za ≤ 25%. (indukcija CYP3A4)
English: Desacetyl diltiazem:
Croatian: desacetildiltiazem:
English: If you had a rash while taking another NNRTI, you may be at higher risk of getting a rash with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Ako ste imali osip tijekom uzimanja drugog NNRTI lijeka, kod Vas postoji veći rizik od pojave osipa tijekom uzimanja lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: Efavirenz/emtricitabine/tenofovir disoproxil has not been studied in patients over the age of 65.
Croatian: Efavirenz/emtricitabin/tenofovirdizoproksil nije ispitivan u bolesnika starijih od 65 godina.
English: NRTIs and NNRTIs NRTIs/Efavirenz
Croatian: Lijekovi klase NRTI i NNRTI lijekovi klase NRTI/efavirenz
English: Recommendation concerning co-administration with Efavirenz/Emtricitabine/Tenof ovir disoproxil Krka (efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil 245 mg)
Croatian: Preporuka za istodobnu primjenu s lijekom Efavirenz/Emtricitabine/Tenof ovir disoproxil Krka (efavirenz 600 mg, emtricitabin 200 mg, tenofovirdizoproksil 245 mg)
English: AUC: ↓ 71% (↓ 67 to ↓ 74) Cmax: ↓ 51% (↓ 46 to ↓ 56) Cmin: ↓ 91% (↓ 88 to ↓ 92)
Croatian: AUC: ↓ 71% (↓ 67 do ↓ 74) Cmax: ↓ 51% (↓ 46 do ↓ 56) Cmin: ↓ 91% (↓ 88 do ↓ 92)
English: Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka should be avoided unless the benefit to the patient outweighs the risk.
Croatian: Treba izbjegavati istodobnu primjenu posakonazola i lijeka Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, osim ako koristi za bolesnika premašuju rizik.
English: What Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is and what it is used for
Croatian: Što je Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i za što se koristi
English: Ethinyloestradiol/Tenofovir disoproxil (-/245 mg q.d.)
Croatian: etinilestradiol/tenofovirdizoproksil (-/245 mg q.d.)
English: Depomedroxyprogesterone acetate (DMPA)/Efavirenz (150 mg IM single dose DMPA)
Croatian: Injekcija: depomedroksiprogesteron acetat (DMPA)/efavirenz (150 mg i.m., jedna doza DMPA)
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be administered concomitantly with adefovir dipivoxil or with medicinal products containing tenofovir alafenamide.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka se ne smije primjenjivati istodobno s adefovirdipivoksilom ili s lijekovima koji sadrže tenofoviralafenamid.
English: AUC: ↓ 60% (↓ 52 to ↓ 68) Cmax: ↓ 62% (↓ 55 to ↓ 78) (CYP3A4 induction)
Croatian: AUC: ↓ 60% (↓ 52 do ↓ 68) Cmax: ↓ 62% (↓ 55 do ↓ 78) (indukcija CYP3A4)
English: Elderly patients are more likely to have decreased hepatic or renal function, therefore caution should be exercised when treating elderly patients with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (see section 4.2).
Croatian: Kod starijih je bolesnika veća vjerojatnost smanjene bubrežne ili jetrene funkcije pa je stoga nužan oprez kad se starije osobe liječe lijekom Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (vidjeti dio 4.2).
English: You must remain under the care of your doctor while taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Croatian: Morate biti pod nadzorom liječnika tijekom uzimanja lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
English: In addition, a K70E substitution in HIV-1 RT has been selected by tenofovir and results in low-level reduced susceptibility to abacavir, emtricitabine, lamivudine and tenofovir.
Croatian: supstitucija u HIV-1 RT što rezultira blagim smanjenjem osjetljivosti na abacavir, emtricitabin, lamivudin i tenofovir.
English: Table 2: Adverse reactions associated with efavirenz/emtricitabine/tenofovir disoproxil listed by the component(s) of efavirenz/emtricitabine/tenofovir disoproxil to which the adverse reactions are attributable
Croatian: Tablica 2: Nuspojave povezane s efavirenzom/emtricitabinom/tenofovirdizoproksilom navedene prema komponenti/komponentama efavirenza/emtricitabina/tenofovirdizoproksila kojima se nuspojave pripisuju efavirenz emtricitabin tenofovirdizoproksil
English: AUC: ↓ 36% (↓ 32 to ↓ 40) Cmax: ↓ 21% (↓ 15 to ↓ 26) Cmin: ↓ 47% (↓ 41 to ↓ 53) (decrease in carbamazepine concentrations: CYP3A4 induction; decrease in efavirenz concentrations: CYP3A4 and CYP2B6 induction)
Croatian: AUC: ↓ 36% (↓ 32 do ↓ 40) Cmax: ↓ 21% (↓ 15 do ↓ 26) Cmin: ↓ 47% (↓ 41 do ↓ 53) (smanjenje koncentracija karbamazepina: indukcija CYP3A4; smanjenje koncentracije efavirenza: indukcija CYP3A4 i CYP2B6)
English: Psychiatric disorders: Common depression (severe in 3, anxiety 3, abnormal dreams 3, insomnia abnormal dreams, insomnia
Croatian: 3, anksioznost abnormalni snovi nesanica abnormalni snovi, nesanica
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may make hormonal contraceptives less likely to work.
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka može smanjiti učinkovitost hormonskih kontraceptiva.
English: Tenofovir disoproxil: AUC: ↔
Croatian: tenofovirdizoproksil: AUC: ↔
English: Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended (see section 4.4 and Table 1).
Croatian: Ne preporučuje se istodobna primjena lijeka Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i didanozina (vidjeti dio 4.4 i Tablicu 1).
English: Cmax: ↑ 11% (↑ 6 to ↑ 16) Cmin: ↔ (CYP3A4 induction)
Croatian: Cmax: ↑ 11% (↑ 6 do ↑ 16) Cmin: ↔ (indukcija CYP3A4)
English: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg film-coated tablets efavirenz/emtricitabine/tenofovir disoproxil (efavirenzum/emtricitabinum/tenofovirum disoproxilum)
Croatian: Efavirenz/Emtricitabine/Tenofovir disoproxil Krka 600 mg/200 mg/245 mg filmom obložene tablete efavirenz/emtricitabin/tenofovirdizoproksil (efavirenzum/emtricitabinum/tenofovirum disoproxilum)
English: Fosamprenavir/ritonavir/Emtricitab ine
Croatian: fosamprenavir/ritonavir/emtricitabi
English: Insufficient data are available to make a dosing recommendation for atazanavir/ritonavir in combination with efavirenz/emtricitabine/tenofovir disoproxil.
Croatian: Nije dostupno dovoljno podataka za određivanje preporučene doze za atazanavir/ritonavir kada se primjenjuje u kombinaciji s efavirenzom/emtricitabinom/tenofovirdizoproksilom.
English: Prior PI-based regimen (N=34)
Croatian: Prethodni režim temeljen na NNRTI lijekovima (N=104)